Results 11 to 20 of about 8,117 (271)

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. [PDF]

New England Journal of Medicine
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating ...
Michael E. Wechsler, P. Nair, B. Terrier, Bastian Walz, A. Bourdin, D. Jayne, D. J. Jackson, F. Roufosse, L. Börjesson Sjö, Ying Fan, M. Jison, C. Mccrae, S. Necander, A. Shavit, C. Walton, Peter A. Merkel   +15 more
semanticscholar   +9 more sources

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia

Internal Medicine, 2020
We herein report a case of refractory chronic eosinophilic pneumonia (CEP) complicated with uncontrolled bronchial asthma, in which remission was successfully induced with single dose of benralizumab, a monoclonal antibody against the alpha-chain of the interleukin-5 receptor.
Kohsuke Isomoto, Tomohisa Baba, Akimasa Sekine, Naoto Aiko, Takashi Ogura   +4 more
exaly   +6 more sources

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Frontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga, Swati Gupta Bhattacharya, Tamotsu Ishizuka   +2 more
exaly   +3 more sources

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study [PDF]

Journal of Clinical Medicine
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Bagnasco D., Beghe B., Blasi F., Bondi B., Braido F., Cameli P., Caminati M., Canonica G. W., Caruso C., Crimi C., El Masri Y., Giordani J., Guarnieri G., Latorre M., Mastrototaro A., Maule M., Menzella F., Micheletto C., Paggiaro P., Pini A., Pini L., Piras S., Senna G., Spanevello A., Vianello A., Visca D., Zappa M.   +26 more
core   +3 more sources

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study [PDF]

Respiratory Research, 2022
Background Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world study examining the baseline characteristics of a large SEA population treated with
Francesco Menzella, Elena Bargagli, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Cristiano Caruso, Stefano Centanni, Maria D’Amato, Stefano Del Giacco, Fausto De Michele, Fabiano Di Marco, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Alessandra Vultaggio, Lucia Simoni, Alessandra Ori, Silvia Boarino, Gianfranco Vitiello, Elena Altieri, Giorgio Walter Canonica   +24 more
doaj   +5 more sources

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma [PDF]

BMJ Open Respiratory Research, 2023
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
Brian J Lipworth, Rory Chan
doaj   +3 more sources

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis [PDF]

Respirology Case Reports, 2023
There is limited data on the use of benralizumab in patients with severe asthma, who have allergic bronchopulmonary aspergillosis (ABPA). We report the case of a 65‐year‐old woman with combined severe eosinophilic and allergic asthma, who presented with ...
Arvindran Alaga, Khairil Ashraff, Nurul Hana Din Khan   +2 more
doaj   +2 more sources

Development of Eosinophilic Granulomatosis With Polyangiitis Despite Anti–Interleukin‐5 Receptor Therapy: The First Case of Bilateral Central Retinal Artery Occlusion During Benralizumab Treatment [PDF]

ACR Open Rheumatol
Here, we describe a rare presentation of eosinophilic granulomatosis with polyangiitis (EGPA) under benralizumab therapy manifesting as bilateral central retinal artery occlusion (CRAO). The patient, a 61‐year‐old man with chronic eosinophilic rhinosinusitis and severe asthma, experienced sudden bilateral visual loss and transient amaurosis ...
Treppo E, Finocchio L, Fazzi B, Pillon M, Quartuccio L.   +4 more
europepmc   +2 more sources

Requalification of patients with severe asthma for biological therapy-Practical 'ReQuaBi' rate decision scheme based on the analytical model. [PDF]

Clin Transl Allergy
Abstract Background Patients with severe asthma experience decreased quality of life due to fixed airway obstruction, hospitalisations and potential fatalities. However, to date, the requalification of severe asthma patients eligible for biological therapy in daily clinical practice remains unstudied.
Majos A, Drissi AB, Kupczyk M, Panek M.
europepmc   +2 more sources

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. [PDF]

PLoS ONE, 2021
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada, Masayuki Nakajima, Masashi Matsuyama, Yuko Morishima, Naoki Arai, Norihito Hida, Taisuke Nakaizumi, Hironori Masuko, Yohei Yatagai, Takefumi Saito, Nobuyuki Hizawa   +10 more
doaj   +2 more sources